A digital view of the world illustrates how Astellas is a global company committed to serving patients worldwide.

News

Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.

Month Year

Month Year

Jan 31, 2006

Recent Progress in the New Drug Development

Japan, January 31, 2006 - Astellas Pharma Inc. ("Astellas"; headquarters: Tokyo; President and CEO: Toichi Takenaka) today announced that it has recently achieved the following progress in its...

Read more about Recent Progress in the New Drug Development
Jan 31, 2006

Ferring and Astellas Enter a License Agreement on Degarelix for the Treatment of Prostate Cancer in Japan (pdf 22KB)

Read more about Ferring and Astellas Enter a License Agreement on Degarelix for the Treatment of Prostate Cancer in Japan (pdf 22KB)
Jan 27, 2006

SNDA for a Fast-Acting Postprandial Hypoglicemic Agent FASTIC Tablet / STARSIS Tablet for Combinaition Therapy with Biguanide was Filed (pdf 11KB)

Read more about SNDA for a Fast-Acting Postprandial Hypoglicemic Agent FASTIC Tablet / STARSIS Tablet for Combinaition Therapy with Biguanide was Filed (pdf 11KB)
Jan 27, 2006

Astellas Has Established Astellas Venture Management in the US

Japan, January 27, 2006 - Astellas Pharma Inc. (headquarters: Tokyo; president and CEO: Toichi Takenaka; hereafter "Astellas") today announced that it has established Astellas Venture Management...

Read more about Astellas Has Established Astellas Venture Management in the US
Jan 26, 2006

Letter of Intent Signed on Domestic Marketing and Joint Development of Quinolone Antibiotic T-3811 (pdf 23KB)

Read more about Letter of Intent Signed on Domestic Marketing and Joint Development of Quinolone Antibiotic T-3811 (pdf 23KB)
Dec 30, 2005

FDA Approves Astellas' VAPRISOL for the Treatment of Euvolemic Hyponatremia (pdf 74KB)

Read more about FDA Approves Astellas' VAPRISOL for the Treatment of Euvolemic Hyponatremia (pdf 74KB)
Dec 26, 2005

NDA for Immunosuppressant FK506 Modified Release Formulation Submitted in the US

Astellas Pharma US, Inc. (headquarters: Deerfield, Illinois; Chairman and CEO: Makoto Nishimura), a US subsidiary of Astellas Pharma Inc. ("Astellas"; headquarters: Tokyo; President and CEO:...

Read more about NDA for Immunosuppressant FK506 Modified Release Formulation Submitted in the US
Dec 21, 2005

Study design and patient background of a large-scale clinical study, INNOVATION, of the angiotensin II receptor blocker MICARDIS was published in medical journal (pdf 2.7MB)

Read more about Study design and patient background of a large-scale clinical study, INNOVATION, of the angiotensin II receptor blocker MICARDIS was published in medical journal (pdf 2.7MB)
Dec 16, 2005

CO-Promotion Agreement between Astellas and sanofi-aventis Group Japan for Hypnotic Myslee (zolpidem tartrate) (pdf 11KB)

Read more about CO-Promotion Agreement between Astellas and sanofi-aventis Group Japan for Hypnotic Myslee (zolpidem tartrate) (pdf 11KB)
Dec 16, 2005

Astellas Transfers Its Group Member Company FMS Co., Ltd. to Canon System Solutions Inc. of the Canon Sales Group (pdf 11KB)

Read more about Astellas Transfers Its Group Member Company FMS Co., Ltd. to Canon System Solutions Inc. of the Canon Sales Group (pdf 11KB)

Show per page

Discover more

Return to media homepage

Follow us

Subscribe to news alerts